Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)

Sunshine Biopharma has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at -$67.0 in Q4 2024.

• For the quarter ending Q4 2024, Non-Current Deferred Tax Liability fell 100.03% year-over-year to -$67.0; the trailing twelve-month figure through Dec 2024 stood at -$67.0 (down 100.03% YoY), and the FY2024 full-year result was -$67.0, down 100.03% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2024 stood at -$67.0, down from $48729.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $225493.0 in Q4 2023, with the low at -$67.0 in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $60415.7 across 3 years, with a median of $43032.0 in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability surged 424.01% — and 2024, when it sank 100.03%.
• Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $43032.0 in 2022, then surged by 424.01% to $225493.0 in 2023, then tumbled by 100.03% to -$67.0 in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at -$67.0 (Q4 2024), $48729.0 (Q3 2024), and $48729.0 (Q2 2024), per Business Quant data.